
PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW122197 |
protein
D4-GDI Signaling PathwayBos taurus
Perforin protein forms pores in the membrane to allow for granzyme B to enter the cell. Granzymes induce apoptosis by activating caspases. D4-GDP dissociation inhibitor (D4-GDI) is a negative regulator of ras-related Rho Family of GTPases. D4-GDI binds Rho GTPases to keep the Rho protein in a GDP-bound and inactivate state. Caspase 3 cleaves D4-GDI into two fragments of 5 kDa and 23 kDa size. The 23 kDa fragment translocates to the nucleus to activate Jun kinase, a regulator of apoptosis. Poly (ADP-ribose) polymerase-1 (PARP) is a substrate for caspase-3. Caspase-3 cleaves PARP into various fragments, this is a hallmark of apoptosis. PARP functions to detect and repair DNA damage. Cleavage of PARP by caspase prevents DNA repair, contributing to cell death. RHO GTPases become activated when released from D4-GDI upon cleavage by caspase-3. RHO GTPases mediate cytoskeleton changes leading to apoptosis and cell death. .
|
Creator: Ana Marcu Created On: September 20, 2018 at 14:57 Last Updated: September 20, 2018 at 14:57 |
PW122221 |
protein
D4-GDI Signaling PathwayRattus norvegicus
Perforin protein forms pores in the membrane to allow for granzyme B to enter the cell. Granzymes induce apoptosis by activating caspases. D4-GDP dissociation inhibitor (D4-GDI) is a negative regulator of ras-related Rho Family of GTPases. D4-GDI binds Rho GTPases to keep the Rho protein in a GDP-bound and inactivate state. Caspase 3 cleaves D4-GDI into two fragments of 5 kDa and 23 kDa size. The 23 kDa fragment translocates to the nucleus to activate Jun kinase, a regulator of apoptosis. Poly (ADP-ribose) polymerase-1 (PARP) is a substrate for caspase-3. Caspase-3 cleaves PARP into various fragments, this is a hallmark of apoptosis. PARP functions to detect and repair DNA damage. Cleavage of PARP by caspase prevents DNA repair, contributing to cell death. RHO GTPases become activated when released from D4-GDI upon cleavage by caspase-3. RHO GTPases mediate cytoskeleton changes leading to apoptosis and cell death. .
|
Creator: Ana Marcu Created On: September 20, 2018 at 15:05 Last Updated: September 20, 2018 at 15:05 |
PW146883 |
drug action
Dabigatran Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:16 Last Updated: October 07, 2023 at 19:16 |
PW128031 |
drug action
Dabigatran Etexilate Action PathwayHomo sapiens
Dabigatran etexilate is an anticoagulant used to prevent venous thromboembolism, it is a prodrug that is administered orally and hydrolyzed via first-pass metabolism into the competitive thrombin inhibitor dabigatran. Dabigatran competitively binds and inhibits thrombin by doing so stops the formation of fibrin and therefore the meshwork for a thrombus. When administered orally, the capsule should not be tampered with in any way prior to administration. The highest concentration of the drug within the body peaks one hour after consumption. The maximum concentration can be prolonged to two hours if a high-fat meal is consumed prior, afterwards the drug is then primarily eliminated through urine and feces. This drug does interact with food, herbs and supplements with anticoagulant and antiplatelet activity should be avoided such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. St. John's wort should also be avoided as it induces an enzyme that can reduce the concentration of active dabigatran. Dabigatran etexilate should be taken with a full glass of water and can be taken with or without the consumption of food.
|
Creator: Selena Created On: July 05, 2023 at 12:42 Last Updated: July 05, 2023 at 12:42 |
PW145737 |
drug action
Dabigatran etexilate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:31 Last Updated: October 07, 2023 at 16:31 |
PW145887 |
drug action
Dabrafenib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:54 Last Updated: October 07, 2023 at 16:54 |
PW176196 |
Dabrafenib Predicted Metabolism PathwayHomo sapiens
Metabolites of Dabrafenib are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 12:34 Last Updated: December 04, 2023 at 12:34 |
PW128246 |
drug action
Dacarbazine Action PathwayHomo sapiens
Dacarbazine, also known as dimethyltriazenoimidazole carboxamide (DTIC) (imidazole carboxamide), is a synthetic antineoplastic agent from the alkylating agent class. It is indicated to treat metastatic malignant melanoma, advanced soft tissue sarcoma, pheochromocytoma, advanced medullary thyroid cancer, and Hidgkin's disease (secondary-line therapy). This drug is a synthetic analog of a naturally occurring purine precursor: 5-amino-1H-imidazole-4-carboxamide (AIC). The mechanism of action of dacarbazine is still undefined, but it is thought to act as an alkylating agent because of its structure. Some other theories include DNA synthesis inhibition by its action as a purine analog and interaction with SH groups. This antineoplastic is not cell cycle-phase specific. DTIC is enzymatically activated in the liver to form the 5-(3-monomethyl-1-triazenyl)-1H-imidazole-4-carboxamide (MTIC) molecule. This chemical product inhibits DNA and RNA synthesis by forming carbonium ions with the formation of diazomethane. It is thought to methylate at the O-6 and N-7 positions on the guanine bases. This drug is administered as an intravenous injection.
|
Creator: Daphnee Created On: August 09, 2023 at 12:08 Last Updated: August 09, 2023 at 12:08 |
PW132293 |
Dacarbazine Drug MetabolismHomo sapiens
Dacarbazine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Dacarbazine passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 20:41 Last Updated: September 21, 2023 at 20:41 |
PW144956 |
drug action
Dacarbazine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:47 Last Updated: October 07, 2023 at 14:47 |